Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 15NIH 2NETWORK 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 13Myeloid 2Classical hematology 1

Conditions

Myelodysplastic Syndromes 2Leukemia 2Leukemia, Myelomonocytic, Chronic 1Congenital Abnormalities 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cytarabine 9Busulfan 7Cyclophosphamide 6Whole-Body Irradiation 5Peripheral Blood Stem Cell Transplantation 5Mycophenolic Acid 5Methotrexate 5fludarabine 4nilotinib 3merphos 3fludarabine phosphate 3Tacrolimus 3Radiotherapy 3Polymerase Chain Reaction 3Mitoxantrone 3Melphalan 3Idarubicin 3Daunorubicin 3Cytogenetic Analysis 3Cyclosporine 3Asparaginase 3bosutinib 2Thioguanine 2Stem Cell Transplantation 2Patient Reported Outcome Measures 2Mesna 2Imatinib Mesylate 2Granulocyte Colony-Stimulating Factor 2Gemtuzumab 2Flow Cytometry 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × Gemtuzumab × Myeloid × Clear all
NCT00028899 2014-02-20

Monoclonal Antibody Plus Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes

Children's Oncology Group

Phase 1 Completed
47 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes

NCT00077116 2012-07-16

Idarubicin, Cytarabine, and Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Secondary to Myelodysplastic Syndrome

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Completed
31 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Congenital Abnormalities, Anemia, Refractory, with Excess of Blasts, Leukemia, Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡